106 related articles for article (PubMed ID: 27405368)
21. Hydrophilic interaction LC-MS/MS analysis of opioids in urine: significance of glucuronide metabolites.
French D; Wu A; Lynch K
Bioanalysis; 2011 Dec; 3(23):2603-12. PubMed ID: 22136049
[TBL] [Abstract][Full Text] [Related]
22. LC-MS-MS Method for Analysis of Opiates in Wastewater During Football Games II.
Gul W; Stamper B; Godfrey M; Gul SW; ElSohly MA
J Anal Toxicol; 2016 Jun; 40(5):330-7. PubMed ID: 27052850
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of dihydrocodeine in hydrocodone positive postmortem specimens.
Jenkins AJ; Lavins ES; Hunek C
J Forensic Leg Med; 2009 Feb; 16(2):64-6. PubMed ID: 19134999
[TBL] [Abstract][Full Text] [Related]
24. Direct and efficient liquid chromatographic-tandem mass spectrometric method for opiates in urine drug testing - importance of 6-acetylmorphine and reduction of analytes.
Andersson M; Stephanson N; Ohman I; Terzuoli T; Lindh JD; Beck O
Drug Test Anal; 2014 Apr; 6(4):317-24. PubMed ID: 23720205
[TBL] [Abstract][Full Text] [Related]
25. Urinary hydrocodone and metabolite distributions in pain patients.
Barakat NH; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Sep; 38(7):404-9. PubMed ID: 24836897
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic monitoring of opioids: a sensitive LC-MS/MS method for quantitation of several opioids including hydrocodone and its metabolites.
Langman LJ; Korman E; Stauble ME; Boswell MV; Baumgartner RN; Jortani SA
Ther Drug Monit; 2013 Jun; 35(3):352-9. PubMed ID: 23666565
[TBL] [Abstract][Full Text] [Related]
27. The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone.
Boswell MV; Stauble ME; Loyd GE; Langman L; Ramey-Hartung B; Baumgartner RN; Tucker WW; Jortani SA
Pain Physician; 2013; 16(3):E227-35. PubMed ID: 23703421
[TBL] [Abstract][Full Text] [Related]
28. [Determination of opiates in biological human samples by liquid chromatography-tandem mass spectrometry].
Xiang P; Shen M; Shen BH; Ma D; Bu J; Jiang Y; Zhuo XY
Fa Yi Xue Za Zhi; 2006 Feb; 22(1):52-4, 57. PubMed ID: 16524188
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and Abuse Potential of Asalhydromorphone, a Novel Prodrug of Hydromorphone, After Intranasal Administration in Recreational Drug Users.
Guenther S; Mickle TC; Barrett AC; Smith A; Braeckman R; Kelsh D; Vince B
Pain Med; 2020 Mar; 21(3):511-520. PubMed ID: 30986302
[TBL] [Abstract][Full Text] [Related]
30. Observations on the urine metabolic profile of codeine in pain patients.
Yee DA; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Mar; 38(2):86-91. PubMed ID: 24396053
[TBL] [Abstract][Full Text] [Related]
31. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
Manchikanti L; Malla Y; Wargo BW; Fellows B
Pain Physician; 2011; 14(2):175-87. PubMed ID: 21412372
[TBL] [Abstract][Full Text] [Related]
32. Dilution of Urine Followed by Adulteration in an Attempt to Deceive the Laboratory.
Feldhammer M; Saitman A; Nguyen L; Milstid B
J Anal Toxicol; 2019 Jan; 43(1):e7-e9. PubMed ID: 30192938
[TBL] [Abstract][Full Text] [Related]
33. Utility of oral fluid in compliance monitoring of opioid medications.
Conermann T; Gosalia AR; Kabazie AJ; Moore C; Miller K; Fetsch M; Irvan D
Pain Physician; 2014; 17(1):63-70. PubMed ID: 24452646
[TBL] [Abstract][Full Text] [Related]
34. Does therapeutic use of tapentadol cause false-positive urine screens for methadone or opiates?
Mullins ME; Hock K; Scott MG
Clin Toxicol (Phila); 2015 Jun; 53(5):493-4. PubMed ID: 25951899
[No Abstract] [Full Text] [Related]
35. Observations on hydrocodone and its metabolites in oral fluid specimens of the pain population: comparison with urine.
Cao JM; Ma JD; Morello CM; Atayee RS; Best BM
J Opioid Manag; 2014; 10(3):177-86. PubMed ID: 24944068
[TBL] [Abstract][Full Text] [Related]
36. Disposition of opioids in oral fluid: Importance of chromatography and mass spectral transitions in LC-MS/MS.
Tuyay J; Coulter C; Rodrigues W; Moore C
Drug Test Anal; 2012 Jun; 4(6):395-401. PubMed ID: 22374679
[TBL] [Abstract][Full Text] [Related]
37. Hydromorphone use for acute pain: Misconceptions, controversies, and risks.
Mazer-Amirshahi M; Motov S; Nelson LS
J Opioid Manag; 2018; 14(1):61-71. PubMed ID: 29508897
[TBL] [Abstract][Full Text] [Related]
38. Illicit drug use correlates with negative urine drug test results for prescribed hydrocodone, oxycodone, and morphine.
Pesce A; West C; Gonzales E; Rosenthal M; West R; Mikel C; Almazan P; Latyshev S; Horn P
Pain Physician; 2012; 15(5):E687-92. PubMed ID: 22996862
[TBL] [Abstract][Full Text] [Related]
39. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
40. Urine drug testing of chronic pain patients. V. Prevalence of propoxyphene following its withdrawal from the United States market.
Puet B; DePriest A; Knight J; Heltsley R; Black DL; Caplan YH; Cone EJ
J Anal Toxicol; 2013; 37(1):1-4. PubMed ID: 23129731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
